OpenLB
Open Library of Bioscience
Advanced Search
Diseases (Basel, Switzerland)
Feb 26, 2025;13 (3):

Herpes Zoster: Risk Factors for Occurrence, Complications, and Recurrence with a Focus on Immunocompromised Patients.

Micha�� Oleszko, Pawe�� Zapolnik, Wojciech Kmiecik, Hanna Czajka
Author Information
  1. Micha�� Oleszko: College of Medical Sciences, University of Rzesz��w, 35-315 Rzesz��w, Poland.
  2. Pawe�� Zapolnik: College of Medical Sciences, University of Rzesz��w, 35-315 Rzesz��w, Poland. ORCID
  3. Wojciech Kmiecik: St. Louis Provincial Specialist Children's Hospital, 31-503 Krak��w, Poland.
  4. Hanna Czajka: College of Medical Sciences, University of Rzesz��w, 35-315 Rzesz��w, Poland.
PMID: 40136611 DOI: 10.3390/diseases13030071

Abstract

BACKGROUND: The varicella-zoster virus is a highly contagious human herpesvirus that primarily causes varicella (chickenpox) as an initial infection, targeting T cells, neurons, as well as skin cells, and can later reactivate to cause herpes zoster (shingles). Following reactivation, the varicella-zoster virus infection can lead to severe complications, the most common of which is postherpetic neuralgia. Risk factors include aging, immunosuppression, chronic diseases such as diabetes, cardiovascular disorders, respiratory conditions, and others.
OBJECTIVE: In this article, we present an analysis of factors increasing the risk of herpes zoster occurrence, complications, and recurrences (in particular in immunocompromised patients).

Keywords

chickenpox communicable disease herpes zoster immunology infections

References

  1. P T. 2013 Apr;38(4):217-27 [PMID: 23785227]
  2. Ther Adv Vaccines. 2015 Jul;3(4):109-20 [PMID: 26478818]
  3. Biomolecules. 2024 Jun 22;14(7): [PMID: 39062454]
  4. Open Forum Infect Dis. 2014 Aug 02;1(2):ofu049 [PMID: 25734121]
  5. Int J Infect Dis. 2021 Mar;104:732-733 [PMID: 33582367]
  6. Am J Epidemiol. 2018 May 1;187(5):1019-1028 [PMID: 29053820]
  7. BMC Infect Dis. 2020 Nov 30;20(1):905 [PMID: 33256624]
  8. Ann Dermatol. 2017 Oct;29(5):602-607 [PMID: 28966517]
  9. Int J Dermatol. 2022 Sep;61(9):1087-1092 [PMID: 35503921]
  10. Dermatol Ther. 2022 Jul;35(7):e15521 [PMID: 35434963]
  11. Dermatol Ther (Heidelb). 2019 Mar;9(1):117-133 [PMID: 30456446]
  12. BMJ. 2023 Nov 8;383:2497 [PMID: 37940164]
  13. Curr Clin Microbiol Rep. 2019 Sep;6(3):156-165 [PMID: 32999816]
  14. Dermatol Ther (Heidelb). 2024 Mar;14(3):569-592 [PMID: 38416279]
  15. Open Forum Infect Dis. 2022 Mar 09;9(5):ofac118 [PMID: 35392454]
  16. J Rheumatol. 2023 Jul;50(7):873-880 [PMID: 36725054]
  17. BMC Infect Dis. 2017 Aug 24;17(1):586 [PMID: 28836951]
  18. BMJ Open. 2014 Jun 10;4(6):e004833 [PMID: 24916088]
  19. MMWR Recomm Rep. 2008 Jun 6;57(RR-5):1-30; quiz CE2-4 [PMID: 18528318]
  20. Respir Res. 2023 Jan 28;24(1):35 [PMID: 36709298]
  21. Viruses. 2022 Jan 19;14(2): [PMID: 35215786]
  22. J Clin Rheumatol. 2022 Mar 1;28(2):e407-e414 [PMID: 33902098]
  23. Dermatol Ther. 2020 Nov;33(6):e13930 [PMID: 32602610]
  24. J Infect Dis. 2020 Aug 4;222(5):798-806 [PMID: 31830250]
  25. J Infect. 2016 Sep;73(3):241-53 [PMID: 27283754]
  26. Arthritis Res Ther. 2022 Jul 28;24(1):180 [PMID: 35902964]
  27. Infection. 2024 Jun;52(3):1009-1026 [PMID: 38236326]
  28. Int J Environ Res Public Health. 2022 Mar 06;19(5): [PMID: 35270787]
  29. Rheumatology (Oxford). 2021 Nov 3;60(11):5042-5051 [PMID: 34508560]
  30. J Virol. 2005 Oct;79(20):12921-33 [PMID: 16188994]
  31. J Am Acad Dermatol. 2021 Sep;85(3):570-571 [PMID: 34217805]
  32. Infect Dis Ther. 2023 Jan;12(1):143-156 [PMID: 36348228]
  33. J Dermatol. 2020 Mar;47(3):236-244 [PMID: 31953880]
  34. Stroke. 2009 Nov;40(11):3443-8 [PMID: 19815828]
  35. J Korean Med Sci. 2018 Dec 20;34(2):e1 [PMID: 30636941]
  36. Viruses. 2023 Feb 05;15(2): [PMID: 36851652]
  37. BMJ. 2005 Jul 16;331(7509):147-51 [PMID: 16020856]
  38. Front Immunol. 2024 Sep 16;15:1458967 [PMID: 39351233]
  39. Hum Vaccin Immunother. 2017 Nov 2;13(11):2606-2611 [PMID: 28933622]
  40. Vaccine. 2024 Mar 19;42(8):1928-1933 [PMID: 38368221]
  41. Glob Health Res Policy. 2020 Jun 5;5:29 [PMID: 32514428]
  42. Nat Rev Dis Primers. 2015 Jul 02;1:15016 [PMID: 27188665]
  43. Arthritis Rheumatol. 2016 Sep;68(9):2328-37 [PMID: 26990731]
  44. Aliment Pharmacol Ther. 2013 Feb;37(4):420-9 [PMID: 23240738]
  45. BMC Infect Dis. 2023 Sep 28;23(1):636 [PMID: 37770849]
  46. Open Forum Infect Dis. 2017 Jan 28;4(1):ofx007 [PMID: 28480280]
  47. J Infect. 2021 Feb;82(2):253-260 [PMID: 33359014]
  48. Am J Clin Dermatol. 2020 Feb;21(1):97-107 [PMID: 31741185]
  49. Dermatol Ther (Heidelb). 2021 Jun;11(3):1009-1026 [PMID: 33959878]
  50. J Am Acad Dermatol. 2021 Sep;85(3):611-618 [PMID: 32622890]
  51. Hum Vaccin Immunother. 2023 Aug;19(2):2256047 [PMID: 37799065]
  52. N Engl J Med. 2020 Jan 16;382(3):211-221 [PMID: 31851795]
  53. Clin Infect Dis. 2023 Feb 8;76(3):e1335-e1340 [PMID: 35796546]
  54. Viruses. 2023 Jul 30;15(8): [PMID: 37632006]
  55. Euro Surveill. 2023 Feb;28(8): [PMID: 36820639]
  56. BMJ Open. 2018 Jun 7;8(6):e020528 [PMID: 29880565]
  57. Vaccine. 2010 Nov 23;28(50):7933-8 [PMID: 20946861]
  58. PLoS One. 2020 Feb 4;15(2):e0228409 [PMID: 32017810]
  59. Dermatol Ther (Heidelb). 2021 Aug;11(4):1119-1126 [PMID: 33999370]
  60. Rheumatology (Oxford). 2019 Oct 1;58(10):1755-1766 [PMID: 30982883]
  61. Vaccine. 2014 Oct 29;32(47):6319-24 [PMID: 24099868]
  62. J Virol. 2021 Oct 27;95(22):e0122721 [PMID: 34468169]
  63. Mayo Clin Proc. 2011 Feb;86(2):88-93 [PMID: 21220354]
  64. Gut Liver. 2019 May 15;13(3):333-341 [PMID: 30602222]
  65. Infect Dis Ther. 2024 Jul;13(7):1461-1486 [PMID: 38896390]
  66. Lupus. 2013 Mar;22(3):238-44 [PMID: 23257402]
  67. J Am Acad Dermatol. 2016 Nov;75(5):950-956.e1 [PMID: 27473453]
  68. Lancet Rheumatol. 2024 Apr;6(4):e247-e251 [PMID: 38373432]
  69. PLoS One. 2015 Jun 11;10(6):e0129043 [PMID: 26065420]
  70. Lancet Healthy Longev. 2022 Apr;3(4):e263-e275 [PMID: 36098300]
  71. J Infect. 2017 Sep;75(3):207-215 [PMID: 28676411]
  72. J Clin Endocrinol Metab. 2022 Jan 18;107(2):586-597 [PMID: 34536279]
  73. Rev Esp Quimioter. 2023 Jun;36(3):223-235 [PMID: 36752132]
  74. Clin Exp Dermatol. 2021 Oct;46(7):1293-1298 [PMID: 33763912]
  75. BMC Infect Dis. 2013 Dec 12;13:586 [PMID: 24330510]
  76. Public Health. 2019 Feb;167:136-146 [PMID: 30660981]
  77. Int J Environ Res Public Health. 2009 Sep;6(9):2344-53 [PMID: 19826547]
  78. J Virol. 2002 Nov;76(22):11425-33 [PMID: 12388703]
  79. BMC Musculoskelet Disord. 2020 Dec 5;21(1):813 [PMID: 33278895]
  80. J Infect Dis. 2020 Aug 4;222(5):708-711 [PMID: 31830261]
  81. Viruses. 2022 Nov 29;14(12): [PMID: 36560671]
  82. Clin Infect Dis. 2017 Mar 1;64(5):572-579 [PMID: 27986685]
  83. Australas J Dermatol. 2021 May;62(2):183-189 [PMID: 33527370]
  84. Front Microbiol. 2023 Nov 17;14:1291868 [PMID: 38075876]
  85. Epidemiol Infect. 2021 May 07;149:e131 [PMID: 33958016]
  86. J Virol. 2006 Dec;80(23):11806-16 [PMID: 16971426]
Journal Article Review

Word Cloud

Created with Highcharts 10.0.0herpeszostervaricella-zosterviruschickenpoxinfectioncellscancomplicationsRiskfactorsBACKGROUND:highlycontagioushumanherpesvirusprimarilycausesvaricellainitialtargetingTneuronswellskinlaterreactivatecauseshinglesFollowingreactivationleadseverecommonpostherpeticneuralgiaincludeagingimmunosuppressionchronicdiseasesdiabetescardiovasculardisordersrespiratoryconditionsothersOBJECTIVE:articlepresentanalysisincreasingriskoccurrencerecurrencesparticularimmunocompromisedpatientsHerpesZoster:FactorsOccurrenceComplicationsRecurrenceFocusImmunocompromisedPatientscommunicablediseaseimmunologyinfections

Similar Articles

Cited By

No available data.